**Registered number: 06641016 Charity number: 1126927**
# **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
**(A Company Limited by Guarantee)**
## **TRUSTEES' REPORT, INDEPENDENT EXAMINER'S REPORT AND FINANCIAL STATEMENTS**
**FOR THE PERIOD ENDED 31 DECEMBER 2022**
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **CONTENTS**
||Page|
|---|---|
|**Reference and Administrative Details of the Charity, its Trustees and Advisers**|1|
|**Trustees' Report**|2 - 11|
|**Independent Examiner's Report**|12 - 13|
|**Statement of Financial Activities**|14|
|**Balance Sheet**|15|
|**Statement of Cash Flows**|16|
|**Notes to the Financial Statements**|17 - 33|
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
## **(A Company Limited by Guarantee)**
## **REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2022**
|**Trustees**|Professor David Maahs, President Elect (appointed 14 October 2021) and
President (since 14 October 2022)|
|---|---|
||Dr Lars Krogvold, Treasurer|
||Dr Carine de Beaufort, Past President (since 14 October 2022)|
||Dr Jamie Wood, Secretary General|
|**Company registered**
**number**
06641016
**Charity registered**
**number**
1126927
**Registered office**
Ellenborough House
Wellington Street
Cheltenham
Gloucestershire
GL50 1YD
**Management Company /**
**Principal Office**
K.I.T. Group GmbH
**Company secretary**
Dr Jamie Wood
**Independent Examiner**
Crowe U.K. LLP
Chartered Accountants
Black Country House
Rounds Green Road
Oldbury
West Midlands
B69 2DG
**Bankers**
Commerzbank
Berlin-Gedächtniskirche
Kurfürstendamm 237
10719 Berlin
Germany
Lloyds Bank Plc
Rotunda
Montpellier
Cheltenham
Gloucestershire
GL50 1SH||
Page 1
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
**(A Company Limited by Guarantee)**
## **TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2022**
The Trustees under Charity Law, who are also the Directors under Company Law, present their report and the financial statements of the Charity for the period ended 31 December 2022. This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.
The International Society for Paediatric and Adolescent Diabetes – ISPAD - is a charitable company, limited by guarantee, incorporated on 8 July 2008 (registration number 06641016) and registered as a charity on 25 November 2008 (charity number 1126927).
## **STRUCTURE, GOVERNANCE AND MANAGEMENT**
## **Governing Document**
The International Society for Paediatric and Adolescent Diabetes (ISPAD or the Society) is governed by its Memorandum and Articles of Association dated 8 July 2008 (last amended 13 June 2023 ); and the UK Charity Governance Code.
## **Principal Activity**
ISPADs overall mission is to bring together professionals from various disciplines with an interest in clinical care, science, education, and advocacy to prevent, treat or cure all forms of diabetes in youth by promoting networking and collaboration. The principal activity of ISPAD is to improve the lives of children, adolescents and young adults with diabetes worldwide, which is accomplished by providing forums, both written (guidelines) and face-toface (scientific meetings, science schools for physicians and for allied healthcare professionals, and postgraduate courses), to physicians and healthcare professionals who provide care for young people with diabetes. To advance further these aims, ISPAD advocates throughout the world for the appropriate provision of medical care and assists international organisations and health services in the delivery of critical diabetes selfcare supplies, such as insulin and glucose test strips, together with educational and promotional material for all children and adolescents with diabetes.
## **Organisational Management**
Each officer of the Charity has a role and responsibilities that are enumerated in the governing document. The Society’s focus on Science, Advocacy and Education is ensured by the officers of the Society who serve as Trustees. They have the ultimate responsibility for fiscal and other decisions in accordance with the Memorandum and Articles of Association, and any bylaws. They consult with the advisory council composed of members of the Society elected each year at the Annual Conference. Advisory council members are specifically sought from different regions of the world so that they are representative of the membership as a whole. The advisory council formally meets with the board twice each year. Between meetings information is exchanged by e-mail and regular conference calls. The dissemination of information on important issues does not need to wait for formal meetings.
The Trustees retain an organisational management group (K.I.T. Group GmbH, Berlin, Germany) who deal with the day-to-day activities of the Society and advises the Trustees in this regard. They have the ability to allocate their employees in any manner that best serves the Society and are granted a license to organise and manage the Annual Conference, the venue for which is selected by the Executive Board. K.I.T. Group reviews the locations, budgets and logistics for the Society and signs the contracts between the management group and venues and exhibitors. K.I.T. Group also collaborates with and provides logistical support to the local conveners and international Scientific Committee, which creates the scientific program and selects speakers.
The management group maintains for the Society records of day-to-day financial transactions and provides reports to the Treasurer and other Trustees at regular intervals. K.I.T. Group processes receipts and transfers funds from the Society’s accounts (used for day-to-day activities) with the approval of the Treasurer, or the Trustees as a whole, during Trustee meetings or after discussions with Trustees. They organise the venue and related activities for Directors’ meetings. The Charity retains both an accounting firm and solicitors. These advise the Trustees on governance, legal, and financial issues.
Page 2
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
## **(A Company Limited by Guarantee)**
## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022**
## **Recruitment and Training of Trustees**
The Trustees of the Society are the current serving officers of the Society. The Trustees are elected by the members at the Annual Conference. The processes for nomination and election of the Trustees are outlined in the Articles and Memorandum (amended 12 October 2012 to allow electronic voting). Trustees have been members of the Society for many years and have contributed to the Society in many areas; e.g., serving on the Advisory Council, organising one or more of the Annual Scientific meetings, science schools or postgraduate courses. Trustees have contributed to the Society’s efforts in Science, Education and Advocacy, which are the pillars of the Society.
Newly elected Trustees spend one year as Trustee-elect and attend the Board/Trustee meetings to gain experience in the Society’s activities: charity governance, finances, grant processing/approvals and other issues involving the organisation and running of the Society. Trustees must be members in good standing of the Society and have participated in the Society’s activities in leadership roles. They receive formal information about the role and responsibilities of a Trustee, and undertake self-paced learning from documents available through the Charity Commission. The year spent serving as Trustee-elect allows on the job experience, guidance and education from the current Trustees prior to assuming the responsibility of a Trustee.
## **Structure and Relationships**
The Trustees/Board of Directors communicate with each other (usually via email) almost daily on the management and direction of the Charity. A regular formal video conference meeting is arranged monthly between the Officers and the Administration Company.
The Trustees retain an organisational management group to assist with the actual day-to-day management of the Charity and the Board has direct oversight of their activities. The Society contracts with the management group to organise and manage the Annual Conference. The management group also provide material support for meetings, organises the Annual Report with the Trustees, which is prepared for distribution at the Annual General Meeting (and by e-mail to the entire membership) and provides a post-conference report for the Trustees after the Annual Conference.
Formal management reports are presented to the Trustees at face-to-face meetings at least twice per year. A written report is presented to the Trustees and members at the Annual General Meeting. Information is exchanged by e-mail or telephone frequently on an ‘as needed’ basis. Financial reports are given to the Treasurer regularly, and the Trustees are updated regularly.
The Trustees, on behalf of the Society, established in 2000 a contract with Wiley, the then publisher of the Society’s journal, Pediatric Diabetes, to provide subscriptions to the journal to all ISPAD members. ISPAD decided to end its relationship with Pediatric Diabetes at the end of 2022 in response to Wiley transferring the journal to Hindawi with dramatic editorial, publishing, and financial changes, including a refusal to publish future ISPAD Guidelines. The Trustees are working on new journal partnership opportunities for ISPAD, including publication of Guidelines. The Trustees, on behalf of the Society, provide scientific oversight and work closely with the conveners on the program of the Annual Conference.
The Society has established agreements of cooperation, collaboration and Memoranda of Understanding with other Charities, companies and Medical Professional Organisations with similar objectives and aims on a need’s basis.
The Trustees contract for facility space, audio-visual supplies and support, and food for the Winter administration meeting (usually held during the international conference on Advanced Technologies & Treatments for Diabetes (ATTD)) and the June meeting usually held during the American Diabetes Association Annual Scientific Meeting (ADA) in the United States.
The Trustees set policies and guidelines for organising and running the Annual Conference.
Page 3
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
## **(A Company Limited by Guarantee)**
## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022**
## **Risk Management**
By contractual agreement, the management group shares the financial risk for the Annual Conference, which usually attracts at least 1,000 attendees from around the world. ISPAD maintains a substantial amount of reserve funds and does not spend money unless convinced that so doing is consistent with the mission of ISPAD, likely to be beneficial and will not deplete its reserves.
The Trustees conduct an annual review of all types of risk by which the Society may be affected. Having reviewed these risks, the Trustees are satisfied that appropriate systems are in place to manage exposure to major risks. The Society holds Trustee liability insurance.
## **Governance**
The Trustees of ISPAD are committed to the Society’s mission and have joined its board because they want to help the charity most effectively carry out its mission for the benefit of patients and families with diabetes. Trustees fully recognise that meeting their charity’s stated public benefit is an ongoing requirement, understand their roles and legal responsibilities, and are committed to good governance, and wish to contribute to ISPAD's continued improvement.
The board acts with integrity, adopting values and creating a culture that helps achieve the organisation’s charitable purposes. The board is aware of the importance of the public’s confidence and trust in charities, and trustees undertake their duties accordingly.
Trustees have the ultimate fiduciary responsibility for managing ISPAD’s funds and assets, protecting its reputation, and maintaining the respect of beneficiaries, other stakeholders and the public by behaving with integrity at all times, even when difficult or unpopular decisions are required.
The board leads the organisation in being transparent and accountable. The charity is open in its work, unless there is good reason for it not to be. The public’s trust that a charity is delivering a public benefit is fundamental to its reputation and success. Making accountability real, through genuine and open two-way communication that celebrates successes and demonstrates willingness to learn from mistakes, helps to build this trust and confidence and earn legitimacy.
## **OUR VISION, MISSION, AND VALUES**
## **Our Vision**
A better world for children, adolescents and young adults with diabetes.
## **Mission Statement**
To bring together professionals from various disciplines with an interest in clinical care, science, education and advocacy to prevent, treat or cure all forms of diabetes in youth.
By promoting networking and collaboration, our aims are:
- To ensure appropriate treatment is available, including medication, self-monitoring equipment and supplies;
- To increase awareness of all types of diabetes and prevent delayed diagnosis;
- To reduce the morbidity and mortality caused by acute and chronic complications;
- To ensure provision of education to youth, families and other caregivers;
- To promote education of diabetes healthcare teams worldwide;
- To foster diabetes research; and
- To prepare and disseminate clinical practice guidelines and standards.
Page 4
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
**(A Company Limited by Guarantee)**
## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022**
## **Our Values**
## **Excellence**
In care, based on rigorous and ethical research with respect for the individual child, adolescent and family and by creating, evaluating and disseminating diabetes knowledge.
## **Collaboration**
The Society collaborates with national and international patient and professional organisations, healthcare providers, policy makers and companies that make products or provide services for children with diabetes.
## **Advocacy**
For children and caregivers to improve awareness that diabetes is different for children compared to adults; to end discrimination based on a child's diabetes; and to obtain increased funding for diabetes treatment, research and prevention.
- To promote the care of children and adolescents with all forms of diabetes mellitus;
- To be an advocate for children and adolescents with all forms of diabetes mellitus; and
- To encourage and support basic, clinical, epidemiological, health, economic and all other relevant research concerning paediatric and adolescent diabetes mellitus.
## **Public Benefit**
Please see below a summary of the principal activities and accomplishments for the year which ISPAD has carried out for the public benefit.
In the furtherance of these objectives, the ISPAD Trustees have complied with the duty in Section 17 of the Charities Act 2011 to have due regard to the Charity Commission’s published general and relevant sub-sector guidance concerning the operation of the Public Benefit requirement under that Act.
## **PRINCIPAL ACTIVITIES AND ACCOMPLISHMENTS**
## **Education**
The extensive Clinical Practice Guidelines, published in 2018, continue to be promulgated and made available on the Society’s website and published in Paediatric Diabetes, the Society’s journal. The Clinical Practice Guidelines are an up-to-date reference for all those concerned with the management of childhood diabetes worldwide. An extensive update and revision of the Clinical Practice Recommendations was published in 2022 (and January 2023). The Guidelines were developed and written by members of the Society, led by an editorial team. This last comprehensive revision consists of 25 chapters and over 250 authors (global distribution, early career and senior, diverse professional background, and persons with diabetes). In addition, an external project officer was appointed to take a lead in supporting the editorial team to ensure the guidelines meet international standards for clinical guidelines and ensure harmonisation of recommendations, content, language and evidence grading across chapters.
The Guidelines are evidence-based and are written using a review process involving input from the entire membership, led by our excellent and enthusiastic volunteer editorial team. A copy of each chapter is available for download by anyone (not only for the members) at no cost from our website www.ispad.org. ISPAD is currently collaborating with partners on the translation of the ISPAD 2022 Guidelines into various languages to facilitate access. In addition, translations into other languages are encouraged with no charge from ISPAD who coordinates these efforts to avoid redundant translations.
In 2022, many activities that in 2020 and 2021 had to be postponed or translated into virtual format, returned to the traditional in person format. This includes the Annual Conference, Science Schools for Physicians and Healthcare Professionals, as well as Postgraduate Courses.
Page 5
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022**
## **Advocacy**
ISPAD collaborates closely with ‘Life for a Child’ and ‘Changing Diabetes in Children’ two major programs whose aim is to improve access to essential diabetes medicines (insulin) and supplies for children in the developing world.
ISPAD continues to work with European Union partners to improve the quality of care throughout the world.
## **Science**
The Annual Conferences involve presentation of research activities, state-of-the-art lectures and topic specific symposia. In 2020 and 2021, ISPAD’s Annual Conference took place virtually over a three-day meeting in October 2020 and 2021 with 1,285 and 1,414 participants respectively. In 2022, the Annual Conference was held in person in Abu Dhabi, United Arab Emirates October 13-16. In total, the meeting brought together 1058 Attendees (781 Face to Face, 277 Virtual), and 369 scientific abstracts were submitted.
ISPAD organises and runs, with volunteer experts, an annual research-oriented Science School for Physicians (held in person in Prague, Czech Republic, in May 2022), as well as a Science School for Allied Healthcare Professionals working in diabetes (held in person in Abu Dhabi in October 2022).
## Applications are competitive for both schools each year.
Visiting Fellowships allow young physicians and healthcare professionals to study research techniques and prepare them to set up research, either in collaboration with the centre in which they study, or to initiate research in a similar area in a more independent manner by providing hands-on experience in an established Centre of Excellence of research in the domain of interest. Applicants present a research proposal for their study as well as references, with letters of support from their hospital or university and from the head of the research centre to which they are applying (directed by an ISPAD member) attesting to the applicant’s acceptance at the centre to pursue the research project as presented. The accepting ISPAD member volunteers their time and centre resources for the project. The funds allow the recipient to travel to the centre and provide support for accommodation. Since 2017 ISPAD collaborates with the Juvenile Diabetes Research Foundation (JDRF) and awards 4 research fellowship, 25,000 dollars each, and since the calendar year 2019, 10 Allan Drash fellowships, of 7,500 dollars each.
The applications are reviewed by the Trustees and the Advisory Committee who rank them on the quality of the application and potential benefits to the applicant. The successful recipient provides ISPAD with a report on the project and is encouraged to submit an abstract to the annual meeting or a paper to the ISPAD journal.
## **Grants from General Funds**
Travel grants are for young physicians and healthcare professionals whose abstracts have been accepted for presentation at the Annual Conference. ISPAD support travel grants (scaled according to geographical location) and special travel grants (full payment of travel, registration and accommodation for members from the developing world).
The abstract quality (scoring as per reviewing process by the Abstract Committee) as well as the country of residence and profession were part of the selection criteria for allocating these grants. Applications from Lower Income Countries (as per World Bank classification) and Allied Healthcare Professionals were explicitly encouraged.
Page 6
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022**
## **Grants Supported by Funds from Restricted Grants**
Grants were obtained for the Science School for Physicians for a 5-day course for 21 young physician scientists (in 2022) to learn how to design a research study, apply proper statistics and write grants. These grants were provided in 2022 by two companies, as well as JDRF.
## **Volunteers**
Members of the Society participate in all aspects of the Society e.g.:
- serving on the Advisory Council
- serving as convener and organising committee members for the Annual Conference
- serving on the Scientific Committee
- reviewing abstracts for the Annual Conference
- acting as faculty for the Science Schools and post graduate courses
- serving on writing committees for the Clinical Practice Guidelines
- advocating for children with diabetes at local, regional and international levels
- working with sponsors to increase contributions
- attending the Annual Conference (primary fund-raising event)
- serving as preceptors for Visiting Fellows
- providing leadership in diabetes care for children and adolescents locally.
## **Members**
The International Society for Paediatric and Adolescent Diabetes has members from more than 100 countries. A membership directory can be found on the ISPAD website (www.ispad.org).
## **FINANCIAL REVIEW AND RESULTS FOR THE PERIOD**
## **Financial Review**
The current period is for the 12 month-period ended 31 December 2022 ('2022'). The prior period is for the year ended 31 December 2021 ('2021').
During the financial period 1 January 2022 to 31 December 2022, expenditure totalled £730,423 (2021: £552,306) and income was £848,597 (2021: £819,264).
Our financial goals are to maintain sufficient funds held in reserve to assure our continued existence under difficult financial situations (poor income years, and unusual economic times), while we continue to support funding for Science Schools, Post Graduate Courses, the Allan Drash Clinical Fellowship, Research Fellowship, Travel Grants, Pediatric Diabetes, Memberships, and special initiatives.
One of the challenges of holding our Annual Conferences in different locations around the world is the widely varying costs and benefits from them. The 2018 Conference in Hyderabad, India was a successful Conference in raising awareness across the wider region, but resulted in a negative balance, while the 45th Annual Conference in Boston, USA in 2019 resulted in a positive balance. The Annual Conferences in 2020 and 2021 were both virtual, with good attendance and they resulted in positive balances.
A negative balance was expected for the Annual Conference on-site in Abu Dhabi 2022. This was both because of an expected reduced number of attendees and reduced sponsorship income. Nonetheless, the location was in line with the overall aim of ISPAD, and the event increased knowledge and raised awareness of diabetes in a region of the world that up to date has never hosted an Annual ISPAD Conference. This expected negative balance was included in the budget to avoid becoming a challenge for the overall financial situation of the Society. Due to a higher number of attendees than expected, and local sponsorships, the event resulted in a positive balance.
Page 7
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022**
A crucial element of our charitable aims is to facilitate access to science and education, especially for young health professionals involved with diabetes. To this end we support travel grants (scaled according to geographical location) and special travel grants (full payment of travel, registration and accommodation for members from the developing world). Starting from July 1, 2020, ISPAD has reduced membership and registration fees for members from Upper-middle-income countries as well as waived membership fees for Lowincome countries.
The COVID-19 pandemic has definitively affected the finances of ISPAD in the previous years and may continue to do so also in the years to come (see below). The pandemic illustrates how quickly the overall economic situation may change, both with respects to potential income and higher expenditures. We have therefore, since February 2020, worked hard to inform members and corporate members/sponsors about the new situations we are facing. In order to maintain our activities, ISPAD must in the coming years focus on keeping costs down, as we expect that income will likely be reduced. This is both because we, like other Societies, expect a reduction in sponsored income as well as reduced conference income due to reduced number of attendees as well as higher conference implementation costs (e.g. venue rental costs, speaker travel expenses).
## **Reserves Policy**
Our policy is to maintain reserves of sufficient funds to provide ongoing support for at least one year of Charity activity. The balance of total reserves at the year end was £1,271,043 (2021: £1,152,869) of which £ 1,135,179 (2021: £1,067,861) was free reserves, this compares with £848,597 of total income in the period ended 31 December 2022 (2021: £819,264), and £135,864 (2021: £85,008) was restricted. Conference income is very unpredictable and the current financial climate demands that we hold a slightly increased reserve. This is considered to be prudent also in light of the fact that corporate sponsorship has become more challenging to obtain.
## **Investment Policy and Objectives**
The overriding philosophy and policy is that the Charity will take only minimal risk in order to preserve funds. The objectives are to garner when possible, reasonable interest on held funds without placing reserves or day-to-day funds at risk.
## **Key risks and uncertainties**
As all charities, ISPAD has been facing increased risks and uncertainties due to the COVID-19 pandemic. Even though the pandemic currently has slowed down, we still have to expect changes and plan for new challenges due to changes in ie. willingness to travel, being paying members of the Society and sponsoring the Society. This leads to continuous difficulties regarding both predicted income as well as expenses.
## **Income:**
During the pandemic, the total number of members for the first time in several years decreased. At ISPAD, we have experienced a stable increase in total membership numbers over a long period. In 2020-2021, we experienced a decrease of approximately 20%. This was mainly due to the needed repeated virtual ISPAD Conference 2021, as in 2020. Even though the virtual conferences were well attended, we missed the effects we usually observe locally. In 2019-2020 we gained a significant amount of new members from North America due to ISPAD 2019 in Boston, while we had a tremendous increase in members from India and neighbouring countries due to our conference in Hyderabad in 2018. The obvious reason for this local effect is a reduced conference fee for paying members. This effect was completely missing for ISPAD Virtual Conference 2020 and 2021. During 2022, we again observed an increase in total membership numbers, mainly because the in-person conference in Abu Dhabi raised local interest and new members form the area. ISPAD will continue to work hard in order to increase the numbers of members, both in specific regions as well as worldwide.
Regarding Corporate Membership and Sponsorship, which are extremely important sources of income for ISPAD, the situation is still uncertain. So far, all key sponsors have maintained their commitments. Still, we are aware that the situation for many of our Corporate collaborators are uncertain, and we should not take their support for granted for the upcoming years.
Page 8
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022**
The Annual Conference in Abu Dhabi 2022, resulted in a positive balance. It is important to underline that a negative balance was expected. This was both because of an expected reduced number of attendees and reduced sponsorship income. Still the location was in line with the overall aim of ISPAD, and the event raised increased knowledge and awareness of diabetes in a region of the world that up to date has never hosted an Annual ISPAD Conference. This expected negative balance was included in the budget to avoid becoming a challenge for the overall financial situation of the Society. Due to higher number of attendees than expected, and local sponsorships, the event resulted in a positive balance.
## **Expenses:**
There are still, and will most likely always be, uncertainties with respects to the allocation and format of several of ISPAD core activities. This includes our science schools, both for physicians and healthcare providers, the ASPED-ISPAD-Lilly Academy, CDiC training and finally the Allan Drash fellowships. The restricted funding from different sponsors for these activities will depend on the activities’ format (in-person or virtual). These activities are of course very important for ISPAD as society, and we have to be flexible, dynamic and pragmatic to maintain as many as them as well, even though the situation caused by the pandemic may return.
In summary, there are more risks and uncertainties than usual in the current situation. Nonetheless, the financial situation is very safe within the fiscal year 2022 due to headroom given by the high level of reserves.
The Trustees undertook detailed planning and forecasting with closely monitoring of the situation since the beginning of the COVID-19 pandemic. Due to this, the Trustees believe that the Charity's financial resources, strong reserves position and contingency planning is sufficient to allow the Charity to continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of these financial statements. There are no material uncertainties about the ability to continue and therefore the financial statements have been prepared on a going concern basis.
## **Looking ahead**
ISPAD has increased engagement with patient advocacy groups during this reporting year, and has encouraged them to meet at our Annual Conferences and to publicise the work and mission of ISPAD. ISPAD has played a major role in communication with the community about COVID-19 safe practices and effects on the diabetes community during 2021, and continued so in 2022. Our Annual Conference for 2023 will be on site in Rotterdam, the Netherlands, with the opportunity to partly participate also virtually.
Due to the COVID-19 pandemic, the war in Ukraine and climate changes, the financial situation is still challenging and rules and regulations for support from industry have changed making it more difficult for ISPAD to receive corporate membership fees or specific grants. We are grateful for those who have been able to continue to support ISPAD. For this reason, ISPAD offers different levels to become a corporate member or sponsor, with different benefits. ISPAD, to enhance its relationship with companies, organizes a specific and strategic meeting (Corporate Advisory Board Meeting) annually with all companies during its Winter Meeting in February. Since 2019, this meeting has been taking place adjacent to the ATTD (Advanced Technologies and Treatments in Diabetes) in order to enable maximum industry attendance. The invoiced year for corporate membership is now the Calendar year (January to December) and hence the accounting will change. The accounting year was transitioned from a July to June financial year to a calendar year by January 1, 2022.
Page 9
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
## **(A Company Limited by Guarantee)**
## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022**
Membership payments are becoming increasingly important. The number of lapsed members might be significantly reduced by improving the payment process and the possibilities to interact with other members. In order to improve payment of membership fees and to overcome some technical issues, ISPAD has requested K.I.T Group GmbH to improve the membership system and extend on the overall experience to enrol members in ISPAD activities. Now, after 8 years from its implementation the system appears to be working well and membership had been steadily increasing every year until COVID-19. As we hoped, we observed an increase during 2022 because of the Annual Conference in Abu Dhabi. Hopefully the increase will continue in 2023, due to the upcoming Annual Conference in Rotterdam..
We still anticipate that ISPAD will likely face the late consequences of the COVID-19 pandemic in the upcoming fiscal years. We expect that some corporate members and sponsors may withdraw as their financial situation is uncertain. Although others may become new members, we may see a reduction in total corporate members and sponsorships. The difficulties in organising the Annual Conference on-site may return, if so we are unsure of how Virtual or hybrid Conferences will affect both the attendance to the conference itself and the total numbers of ISPAD members. If we hopefully are to arrange on-site activities in the future as planned, expenses may likely increase as a consequence of higher international airline expenses. Therefore, maintaining reserves of sufficient funds are more important than ever for ISPAD.
We have also initiated a revised accounting system for invoicing to be performed by K.I.T. Group in conjunction with and approval by the ISPAD Treasurer. This system is designed to provide redundancy and avoid missing opportunities for ISPAD funding.
## **Charity Governance Code**
ISPAD aims to address the seven principles of the Charity Governance Code https://www.charitygovernancecode.org/en/front-page
1. Organisational purpose: to facilitate the mission of ISPAD to improve the lives of children, adolescents and young adults with diabetes worldwide. To do this we provide forums, both written (guidelines, e-Learning) and face-to-face (scientific meetings, science schools for physicians and for allied healthcare professionals, and postgraduate courses), to physicians and healthcare professionals who provide care for young people with diabetes. We have three main pillars to achieve our mission: science, education and advocacy.
2. Leadership; the Trustees comprise an Executive Board and are advised by an Advisory Committee. We take collective responsibility for the Board’s decisions. The roles of each Trustee are clearly identified (Winter Executive Meeting February 2020). Since 2017, the Executive Board now includes a Communications Director to facilitate effective communication with the membership and community.
3. Integrity; the Executive Board acts with integrity and is conscious of how it is perceived by the membership and the public. A corporate liaison officer was appointed in February 2018 to assist with communication and perception in the community, the “Diabetes Online Community” including consumer “bloggers”. We facilitate their meetings at our Annual Conference and meet with them at meetings organized by the consumer organization Children With Diabetes (February 2020). Conflicts of interest are declared.
4. Decision-making, risk and control; the Board makes sure that operational plans and budgets are in line with the charity’s purpose. The Board invested in forward planning by expenses for representatives to meet and teach in India (2016-2020), the country with the second largest number of children with diabetes, and in Africa (2019, 2020)
5. Board effectiveness; the Board acts as an effective team and encourages members of the Advisory Board to set up Special Interest Groups at the Annual Conference in October 2017 onwards. Trustees are reflective of their performance and discuss areas that can be strengthened.
6. Equality, Diversity and Inclusion; the Board encourages diversity in the membership of committees, and in special non-physician positions on the Advisory Board.
7. Openness and accountability; the Board communicates with the membership by the Annual General Meeting and by monthly newsletters sent by email. The President writes special messages since 2017 which can be sourced on the Society’s website. The Annual Report is circulated to the Membership and is available to the Public.
Page 10
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022**
## **Statement of Trustees' Responsibilities**
The Trustees (who are also directors of the International Society for Paediatric and Adolescent Diabetes for the purposes of company law) are responsible for preparing the Trustees’ Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards).
Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Charitable Company and of the incoming resources and application of resources, including the income and expenditure, of the Charitable Company for that period. In preparing these financial statements, the Trustees are required to:
- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charitable Company will continue in business.
The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charitable Company’s transactions, disclose with reasonable accuracy at any time the financial position of the Charitable Company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the Charity’s constitution. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The report of the Trustees has been prepared in accordance with the special provisions relating to small companies subject to the small companies regime within part 15 of the Companies Act 2006.
Approved by the Board of Trustees of The International Society for Paediatric and Adolescent Diabetes on 23 September 2023 and signed on its behalf by:
Dr Lars Krogvold Trustee
Page 11
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2022**
## **Independent Examiner's Report to the Trustees of The International Society for Pediatric and Adolescent Diabetes ('the Charity')**
I report to the charity Trustees on my examination of the accounts of the Charity for the period ended 31 December 2022.
This report is made solely to the charitable company's trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and the charitable company's trustees as a body in accordance with section 154 of the Charities Act 2011. My independent examiner's work has been undertaken so that I might state to the charitable company's trustees those matters I am required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's trustees as a busy for my independent examiner's work, for this report, or the opinions I have formed.
## **Responsibilities and Basis of Report**
As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').
Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.
## **Independent Examiner's Statement**
Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of The Association of Chartered Certified Accountants, which is one of the listed bodies.
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:
1. accounting records were not kept in respect of the Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
Page 12
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
**INDEPENDENT EXAMINER'S REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022**
Signed: Helen Blundell
Dated: 25 September 2023
**Crowe U.K. LLP** Chartered Accountants Black Country House Rounds Green Road Oldbury West Midlands B69 2DG
Page 13
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2022**
|**Note**
**Income from:**
Donations
Charitable activities:
Membership income
Coporate sponsorship income
Corporate membership
JDRF Fellowship
Conference income
_._ Other charitable activities
Other income: Royalties
**Total income**
**Expenditure on:**
Charitable activities
4
**Total expenditure**
**Net income**
Transfers between funds
13
**Net movement in funds**
**Reconciliation of funds:**
Total funds brought forward
Net movement in funds
**Total funds carried forward**|**Unrestricted**
**funds**
**2022**
**£**
**-**
**144,305**
**-**
**132,878**
**-**
**84,589**
**-**
**13,255**
**375,027**
**273,929**
**273,929**
**101,098**
**(33,780)**
**67,318**
**1,067,861**
**67,318**
**1,135,179**|**Restricted**
**funds**
**2022**
**£**
**-**
**-**
**316,918**
**-**
**156,652**
**-**
**-**
**-**
**473,570**
**456,494**
**456,494**
**17,076**
**33,780**
**50,856**
**85,008**
**50,856**
**135,864**|**Total**
**funds**
**2022**
**£**
**-**
**144,305**
**316,918**
**132,878**
**156,652**
**84,589**
**-**
**13,255**
**848,597**
**730,423**
**730,423**
**118,174**
**-**
**118,174**
**1,152,869**
**118,174**
**1,271,043**|_Total_
_funds_
_18 months to_
_31 December_
_2021_
_£_
_400_
_138,324_
_138,841_
_209,489_
_94,936_
_225,738_
_1,612_
_9,924_|
|---|---|---|---|---|
|||||_819,264_|
|||||_552,306_|
|||||_552,306_|
|||||_266,958_
_-_|
|||||_266,958_|
|||||_885,911_
_266,958_|
|||||_1,152,869_|
The notes on pages 17 to 33 form part of these financial statements.
Page 14
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee) REGISTERED NUMBER: 06641016**
## **BALANCE SHEET AS AT 31 DECEMBER 2022**
|**Note**
**Current assets**
Debtors
10
Cash at bank and in hand
Creditors: amounts falling due within one
year
11
**Net current assets**
**Total assets less current liabilities**
Creditors: amounts falling due after more
than one year
12
**Total net assets**
**Charity funds**
Restricted funds
13
Unrestricted funds
13
**Total funds**|**285,838**
**1,572,277**
**1,858,115**
**(543,825)**|**2022**
**£**
**1,314,290**
**1,314,290**
**(43,247)**
**1,271,043**
**135,864**
**1,135,179**
**1,271,043**|_203,178_
_1,416,407_
_1,619,585_
_(456,448)_|_2021_
_£_
_1,163,137_
_1,163,137_
_(10,268)_
_1,152,869_
_85,008_
_1,067,861_
_1,152,869_|
|---|---|---|---|---|
The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.
The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.
The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.
The financial statements were approved and authorised for issue by the Trustees on _________________________________________________ 23 September 2023 and signed on their behalf by:
**Dr Lars Krogvold** Trustee
The notes on pages 17 to 33 form part of these financial statements.
Page 15
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
## **(A Company Limited by Guarantee)**
## **STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2022**
|**Note**
**Cash flows from operating activities**
Net cash from operating activities
15
**Change in cash and cash equivalents in the year**
Cash and cash equivalents at the beginning of the year
**Cash and cash equivalents at the end of the year**
16|**31**
**December**
**2021**
**£**
**155,870**
**155,870**
**1,416,407**
**1,572,277**|_30 June_
_2020_
_£_
_234,030_|
|---|---|---|
|||**234,030**
_1,182,377_|
||||
|||_1,416,407_|
The notes on pages 17 to 33 form part of these financial statements
Page 16
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **1. General information**
The International Society for Pediatric and Adolescent Diabetes (ISPAD) is a charitable company, limited by guarantee, (registration number 06641016 England & Wales) and the Charity Commission (charity number 1126927). The registered office address is Harrison Clark Rickerbys Limited, Ellenborough House, Wellington Street, Cheltenham, Gloucestershire, GL50 1YD.
## **2. Accounting policies**
## **2.1 Basis of preparation of financial statements**
These financial statements present information about the Charity as an individual undertaking. The current period is for the year ended 31 December 2022 ('2022'). The prior period is for the 18 monthperiod ending 31 December 2021 ('2021').
The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Companies Act 2006 and the Charities Act 2011.
The International Society for Pediatric and Adolescent Diabetes meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.
## **2.2 Going concern**
The Trustees have undertaken detailed planning and forecasting and continue to closely monitor the long-term financial impact of COVID-19 as well as the developing global financial situation. As described in the Trustees' Report membership income was impacted during 2020 and 2021. Although the Trustees observed a positive membership income in 2022, there are uncertainties over future corporate income and income and costs associated with conferences, fellowships and events.
Despite the current circumstances the Trustees believe that the Charity's financial resources, strong reserves position and contingency planning is sufficient to allow the Charity to continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of these financial statements. There are no material uncertainties about the ability to continue and therefore the financial statements have been prepared on a going concern basis.
## **2.3 Income**
Income is recognised in the financial statements when the Charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.
Membership income is recognised in line with the financial year. Membership income for future years is deferred.
Page 17
**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **2. Accounting policies (continued)**
## **2.4 Expenditure**
All expenditure is accounted for on an accruals basis. Support costs are apportioned to cost activities based on the estimated amount attributable to that cost in the year on the basis of the estimated time spent on that activity. The irrecoverable element of VAT is included with the item of expense to which it relates.
Charitable activities comprise all expenditure incurred directly relating to the objects of the Charity.
Grants are recognised when a constructive obligation arises that results in the payment being unavoidable.
Governance costs include the costs connected with the Charity’s constitutional and statutory requirements.
Charitable activities are costs incurred on the company's operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.
## **2.5 Foreign currencies**
Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date.
Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.
Exchange gains and losses are recognised in the Statement of Financial Activities.
The functional currencies of ISPAD are considered to be Euros and US Dollars because these are the currencies used by the members of the Society in the primary economic environment in which the charity operates, Europe and the rest of the world. The financial statements are presented in pounds sterling.
## **2.6 Taxation**
As a registered Charity the entity is entitled to taxation exemptions on all its income and gains, properly applied for its charitable purposes.
## **2.7 Debtors**
Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid.
## **2.8 Cash at bank and in hand**
Cash is represented by cash in hand and deposits with financial institutions.
## **2.9 Creditors**
Creditors are recognised once there is a legal or constructive obligation that commits the Charity to the obligation.
Page 18
**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **2. Accounting policies (continued)**
## **2.10 Financial instruments**
The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.
## **2.11 Fund accounting**
Unrestricted funds expendable at the discretion of the Trustees in furtherance of objectives and administration of the Charity.
Restricted funds are to be used for specified purposes laid down by the donor. Expenditure for those purposes is charged to the restricted fund.
## **3. Critical accounting estimates and areas of judgement**
Preparation of the financial statements requires management to make any significant estimates and judgements where necessary. The items in the financial statements where material estimates and judgements have been made include:
## I **mpairment of debtors**
The charity makes an estimate of the recoverable value of membership debtors. When assessing impairment management considers historical experience. See note 11 for the net carrying amount of debtors.
Page 19
**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **4. Analysis of expenditure on charitable activities**
## **Summary by fund type**
|**Unrestricted**
**funds**
**2022**
**£**
Membership costs
146,255
Conference costs
75,229
Grants and Prizes (note 6)
26,573
ISPAD Science School for Physicians
-
ISPAD Science School for Healthcare Professionals
2,116
PETCA/PETCWA Research and projects
1,744
Allan Drash Fellowship
-
Discovery of Insulin (Children's Book)
-
FID-ISPAD Research Grant
-
ISPAD Guidelines
1,405
ISPAD-JDRF Fellowship
20,607
ADECA
-
**Total 2022**
273,929|**Restricted**
**funds**
**2022**
**£**
-
-
6,804
45,117
21,384
-
115,076
2,759
42,684
16,748
140,520
65,402
456,494|**Total**
**2022**
**£**
**146,255**
**75,229**
**33,377**
**45,117**
**23,500**
**1,744**
**115,076**
**2,759**
**42,684**
**18,153**
**161,127**
**65,402**|
|---|---|---|
|||**730,423**|
Page 20
**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **4. Analysis of expenditure on charitable activities (continued)**
## **Summary by fund type (continued)**
|Membership costs
Conference costs
Grants and Prizes (note 6)
ISPAD Science School for Physicians
ISPAD Science School for Healthcare Professionals
PETCA/PETCWA Research and projects
Allan Drash Fellowship
Discovery of Insulin (Children's Book)
ISPAD - CDiC -T1D Training (Cambodia)
ISPAD-JDRF Fellowship
Other
_Total 2021_|_Unrestricted_
_funds_
_18 months to_
_31_
_December_
_2021_
_£_
_172,874_
_44,187_
_19,451_
_24,148_
_8,127_
_1,182_
_22,149_
_-_
_-_
_64,234_
_3,327_
_359,679_|_Restricted_
_funds_
_18 months to_
_31_
_December_
_2021_
_£_
_-_
_-_
_9,451_
_(2,605)_
_-_
_-_
_66,588_
_1,612_
_25,098_
_92,483_
_-_
_192,627_|_Total_
_18 months to_
_31_
_December_
_2021_
_£_
_172,874_
_44,187_
_28,902_
_21,543_
_8,127_
_1,182_
_88,737_
_1,612_
_25,098_
_156,717_
_3,327_|
|---|---|---|---|
||||_552,306_|
Page 21
**(A Company Limited by Guarantee)**
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **5. Analysis of expenditure by activities**
|Membership costs
Conference costs
Grants and Prizes (note 6)
ISPAD Science School for Physicians
ISPAD Science School for Healthcare Professionals
PETCA/PETCWA Research and projects
Allan Drash Fellowship
Discovery of Insulin (Children's Book)
FID-ISPAD Research Grant
ISPAD Guidelines
ISPAD-JDRF Fellowship
ADECA
**Total 2022**|**Activities**
**undertaken**
**directly**
**2022**
**£**
54,414
67,706
30,039
44,215
20,915
1,735
94,362
2,759
42,471
17,971
141,792
65,402
583,781|**Support**
**costs**
**2022**
**£**
91,841
7,523
3,338
902
2,585
9
20,714
-
213
182
19,335
-
146,642|**Total**
**funds**
**2022**
**£**
**146,255**
**75,229**
**33,377**
**45,117**
**23,500**
**1,744**
**115,076**
**2,759**
**42,684**
**18,153**
**161,127**
**65,402**|
|---|---|---|---|
||||**730,423**|
Page 22
**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **5. Analysis of expenditure by activities (continued)**
|_Activities_
_undertaken_
_directly_
_18 months to_
_31 December_
_2021_
_£_
Membership costs
_-_
Conference costs
_10,962_
Grants and Prizes (note 6)
_25,580_
ISPAD Science School for Physicians
_17,114_
ISPAD Science School for Healthcare Professionals
_3,698_
PETCA/PETCWA Research and projects
_1,182_
Allan Drash Fellowship
_66,588_
Discovery of Insulin (Children's Book)
_1,612_
ISPAD-CDiC- T1D Training (Cambodia)
_25,098_
ISPAD-JDRF Fellowship
_92,483_
Other
_-_
_Total 2021_
_244,317_|_Support_
_costs_
_18 months to_
_31_
_December_
_2021_
_£_
_172,874_
_33,225_
_3,322_
_4,429_
_4,429_
_-_
_22,149_
_-_
_-_
_64,234_
_3,327_
_307,989_|_Total_
_funds_
_18 months to_
_31_
_December_
_2021_
_£_
_172,874_
_44,187_
_28,902_
_21,543_
_8,127_
_1,182_
_88,737_
_1,612_
_25,098_
_156,717_
_3,327_|
|---|---|---|
|||_552,306_|
Page 23
**(A Company Limited by Guarantee)**
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **6. Grants and prizes**
|ISPAD Prize for Achievement
Special Travel Grants
Young Investigator Award
ISPAD Prize for Innovation
Lestradet Award
Standard Travel Grants
Hero Award
Patient Advocates
Prize Winners|**12 months**
**to 31**
**December**
**2022**
**£**
**-**
**4,782**
**-**
**-**
**-**
**21,791**
**669**
**-**
**6,135**
**33,377**|_18 months to_
_31_
_December_
_2021_
_£_
_2,374_
_1,868_
_1,164_
_2,470_
_2,415_
_13,257_
_1,028_
_1,004_
_-_|
|---|---|---|
|||_25,580_|
Details of the winners of ISPAD prizes and fellowships is available at; www.ispad.org/?page=ISPADPrizeWinners.
All grants, prizes and fellowships are to individuals. During the year grants were paid to 33 individuals.
Page 24
**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **7. Support costs**
|Meeting expenses
Insurance
Bank Charges
Credit Card fees
Membership Dues
Management charge
Printing, postage and stationery
Advertising and promotion
**Governance costs**
Independent Examiner's fees
Legal fees
Exchange loss/ (gain)
Webinars
Sundry|**12 months**
**to 31**
**December**
**2022**
**£**
**1,936**
**820**
**4,106**
**3,183**
**4,961**
**162,397**
**37**
**4,369**
**24,823**
**433**
**(65,268)**
**4,458**
**387**
**146,642**|_18 months to_
_31_
_December_
_2021_
_£_
_532_
_1,472_
_3,339_
_7,406_
_-_
_190,378_
_265_
_6,626_
_12,640_
_2,246_
_74,490_
_8,595_
_-_|
|---|---|---|
|||_307,989_|
## **Exchange rate gain/loss**
This is not a trading gain as ISPAD does not trade currencies. It is an ‘accounting adjustment’ and represents the difference in value of non-sterling balances at the year end in comparison to the start of the year where different exchange rates were in effect. As an example a balance of $10,000 at the start of the financial year might be worth £7,600 (at a USD/GBP exchange rate of 0.76) and at the end of the year that might have changed to £7,870 (at a USD/GBP exchange rate of 0.787). This would result in an apparent gain of £270 while in fact there had been no change to the $10,000 held.
The foreign exchange loss is included in support costs and was £65,268 (2021: £74,490 gain).
## **Independent Examiner's fees**
The independent examiner's fee reported during the year is significantly higher than the comparable period because this is the first year that an accrual is being input into the accounts to include the current year fees. The figure reported is made up of fees for 2022 of £9,500, and fees for 2021 of £15,323.
Page 25
**(A Company Limited by Guarantee)**
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **8. Independent examiner's remuneration**
||**12 months**|_18 months to_|
|---|---|---|
||**to 31**|_31_|
||**December**|_December_|
||**2022**|_2021_|
||**£**|_£_|
|Fees payable to the Charity's independent examiner for the independent|||
|examination of the Charity's annual accounts|**21,823**|_9,640_|
|Fees payable to the Charity's independent examiner in respect of:|||
|All assurance services not included above|**3,000**|_3,000_|
## **9. Trustees' remuneration and expenses**
During the period, no Trustees received any remuneration or other benefits _(2021 - £NIL)_ .
During the period ended 31 December 2022, expenses totalling _£_ 7,225 were reimbursed or paid directly to 3 Trustees _(2021 - £532 to 4 Trustees)_ . Expenses related to travel, accomodation and subsistence.
## **10. Debtors**
|**Due within one year**
Trade debtors
Prepayments and accrued income|**2022**
**£**
**285,838**
**-**
**285,838**|_2021_
_£_
_197,868_
_5,310_|
|---|---|---|
||||
|||_203,178_|
Page 26
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
## **(A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **11. Creditors: Amounts falling due within one year**
|Trade creditors
Accruals and deferred income
Deferred income at 1 January 2022
Resources deferred during the year
Amounts released from previous periods|**2022**
**£**
**245,550**
**298,275**
**543,825**
**2022**
**£**
**261,708**
**126,419**
**(251,440)**
**136,687**|_2021_
_£_
_190,907_
_265,541_|
|---|---|---|
||||
|||_456,448_|
|||_2021_
_£_
_158,227_
_261,708_
_(158,227)_|
||||
|||_261,708_|
Deferred income relates to membership subscriptions, corporate membership for future years and the JDRF Fellowship.
## **12. Creditors: Amounts falling due after more than one year**
||**2022**|_2021_|
|---|---|---|
||**£**|_£_|
|Accruals and deferred income|**43,247**|_10,268_|
Page 27
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **13. Statement of funds**
## **Statement of funds - current period**
|**Unrestricted funds**
General Funds - all funds
**Restricted funds**
ISPAD SSHP
Alan Drash Fellowship
Innovation Prize
Wedcasting sponsorship
Young Investigator's Award
Lestradet Award
Discovery of Insulin
ASPED-ISPAD Lilly Diabetes
Postgraduate course
JDRF Fellowship
Novo Nordisk/Lily SSP
Lily Prize for Achievement
Hero Award
ISPAD Guidelines 2022
ADECA
FID- ISPAD Grant
Changing Diabetes in Children
**Total of funds**|**Balance at**
**1 July 2020**
**£**
**1,067,861**
**-**
**-**
**13,646**
**3,254**
**6,877**
**10,174**
**-**
**8,809**
**2,453**
**34,816**
**3,911**
**1,068**
**-**
**-**
**-**
**-**
**85,008**
**1,152,869**|**Income**
**£**
**375,027**
**28,933**
**106,391**
**6,181**
**-**
**4,927**
**5,915**
**12,010**
**-**
**156,652**
**42,349**
**5,999**
**-**
**8,220**
**48,835**
**42,687**
**4,471**
**473,570**
**848,597**|**Expenditure**
**£**
**(273,929)**
**(21,384)**
**(115,076)**
**(1,749)**
**-**
**(1,097)**
**(1,097)**
**(2,759)**
**-**
**(140,520)**
**(45,117)**
**(2,193)**
**(669)**
**(16,748)**
**(65,402)**
**(42,683)**
**-**
**(456,494)**
**(730,423)**|**Transfers**
**in/out**
**£**
**(33,780)**
**-**
**8,685**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**-**
**8,528**
**16,567**
**-**
**-**
**33,780**
**-**|**Balance at**
**31**
**December**
**2022**
**£**
**1,135,179**|
|---|---|---|---|---|---|
||||||**7,549**
**-**
**18,078**
**3,254**
**10,707**
**14,992**
**9,251**
**8,809**
**18,585**
**32,048**
**7,717**
**399**
**-**
**-**
**4**
**4,471**|
||||||**135,864**|
||||||**1,271,043**|
Page 28
## **THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES**
## **(A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **13. Statement of funds (continued)**
## **Statement of funds - prior year**
|**Unrestricted funds**
General Funds - all funds
**Restricted funds**
ISPAD SSHP
Alan Drash Fellowship
Innovation Prize
Wedcasting sponsorship
Young Investigator's Award
Lestradet Award
Discovery of Insulin
ASPED-ISPAD Lilly Diabetes
Postgraduate course
JDRF Fellowship
Novo Nordisk/Lily SSP
Lily Prize for Achievement
Hero Award
ISPAD Guidelines 2022
ADECA
FID- ISPAD Grant
Changing Diabetes in Children
**Total of funds**|_Balance at_
_1 July 2020_
_£_
_843,665_
_-_
_-_
_11,928_
_3,254_
_5,946_
_5,047_
_-_
_8,809_
_-_
_7,262_
_-_
_-_
_-_
_-_
_-_
_-_
_42,246_
_885,911_|_Income_
_£_
_583,875_
_-_
_66,586_
_4,190_
_-_
_2,095_
_7,542_
_1,612_
_-_
_94,936_
_24,949_
_6,285_
_2,096_
_25,098_
_-_
_-_
_-_
_235,389_
_819,264_|_Expenditure_
_£_
_(359,679)_
_-_
_(66,586)_
_(2,472)_
_-_
_(1,164)_
_(2,415)_
_(1,612)_
_-_
_(92,483)_
_2,605_
_(2,374)_
_(1,028)_
_(25,098)_
_-_
_-_
_-_
_(192,627)_
_(552,306)_|_Transfers_
_in/out_
_£_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_
_-_|_Balance at_
_30 June_
_2020_
_£_
_1,067,861_|
|---|---|---|---|---|---|
||||||_-_
_-_
_13,646_
_3,254_
_6,877_
_10,174_
_-_
_8,809_
_2,453_
_34,816_
_3,911_
_1,068_
_-_
_-_
_-_
_-_|
||||||_85,008_|
||||||_1,152,869_|
Page 29
**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **15. Statement of Funds (continued)**
## I **SPAD Science School for Healthcare Professionals**
This is funds used to support the Science School for Healthcare Professionals which is a three day course in the field of childhood diabetes to learn about research development, statistics and grant writing.
## **Allan Drash Fellowship**
Allan Drash was one of ISPAD’s founding members and in his memory ISPAD offers a 6 week clinical fellowship. Applications are invited from members below 45 years of age. A report must be submitted to the ISPAD Steering Committee within 1 year after fellowship.
## **The ISPAD Prize for Innovation in Pediatric Diabetes Care**
Sponsored by NovoNordisk within their DAWN™ Youth Initiative, this prize is for any professional, group or individual who has made a significant (non-commercial) innovation in pediatric diabetes care. DAWN™ Youth is a global programme to guide the wider diabetes community to address the unmet needs of young people with diabetes, their families, peers and healthcare professionals. This prize puts the focus on diabetes in childhood by recognising innovations to improve health and quality of care for children and young people.
## **Discovery of Insulin**
100 years of the discovery of insulin was celebrated in 2021 and 2022. To celebrate, ISPAD prepared various communications across its website and social media. A “comic book” was devised for young people (Insulin: The Incredible Discovery), describing the discovery of Insulin (with drawings by Rebecca Redmond and story by Jade Bryne). The comic book was disseminated at several meetings/events last year.
## **Webcasting**
The webcasting fund was initially created for costs related to ISPAD's first webcasting Platform in 2014 (Annual Conference in Toronto). Since 2015, ISPAD has a new Resource Platform, for which the funding and related costs are now managed as part of the conference budget, managed by K.I.T Group, in close collaboration with ISPAD.
## **E-Learning**
New educational tools include the web based e-learning programs. These allow a wider access to information and a continuous auto evaluation. ISPAD was invited by ESPE to develop the Diabetes Module in the e-learning portal created by the team of Professor Sten Drop in Rotterdam. This Diabetes Module is based on our Clinical Practice Consensus Guidelines. ISPAD Members are able to access the e-learning portal.
## **The ISPAD-ASPED Lilly diabetes postgraduate course**
The ISPAD/ASPED/Lilly diabetes postgraduate course (previously described as the Post Grad Course Arabian) is an initiative from ASPED in collaboration with ISPAD. The aim of the course is to empower and update physicians practicing in the Arab countries who are involved in the care of young people with diabetes and is intended to be a platform to share expertise, research and development in the field of diabetes.
## **ISPAD JDRF Fellowship**
JDRF has signed a MoU with ISPAD with the aim to award each year for three years starting in 2017, four grants of $25,000 to award the four best research projects submitted by young researchers, who are ISPAD members, aged 40 or below. The grant can be spent in a hosting center of excellence but also at their own center.
Page 30
**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **15. Statement of Funds (continued)**
## **SWEET Project**
The aim of SWEET is to reduce inequalities in access to and quality of pediatric diabetes care. Shortcomings and inequalities in this care are mainly due to the underlying differences in systems, and the most straightforward solution to this problem is a network of pediatric diabetes centers worldwide, connected through common objectives and standards, making it possible to benchmark resources and results. The SWEET registry was established in 2008 for this purpose. The ISPAD@SWEET initiative strives to include centers from the developing world. Eli Lilly gave €30,000 for the first year of the project to equally support both smaller and larger centers, in total eight clinics, from developing countries to become respectively Center of Reference and Associated Centers of SWEET and start up a registry.
## **Novo Nordisk/Lily SSP 2018**
These are funds to support the Science School for Physicians.
The remaining restricted funds are donations or grants which must be awarded to individuals.
## **Hero Award**
This award identifies and honours non-clinicians from around the world who have developed projects with a broad impact, thus contributing to improving and transforming the lives of many young people with diabetes. More information can be found here: https://www.ispad.org/page/ISPADHEROAWARD.
## **ISPAD Guidelines 2022**
ISPAD’s Clinical Pratice consensus guidelines are the only comprehensive set of clinical recommendations for children, adolescents, and young adults with diabetes worldwide. Authors include experts from across the globe and a chapter on limited care for developing healthcare systems has also been developed. A great amount of work is involved in reviewing these chapters every four years. In order to ensure consistency and solid research across all chapters, ISPAD paid for the support of a freelancing project officer to help with his specific assignment. The final set of guidelines for 2022 are available here: https://www.ispad.org/page/ISPADGuidelines2022
## **ADECA**
The Allied Healthcare Professionals Pediatric Diabetes Educator Course for Africa (ADECA) is a diabetes education and management course that targets qualified nurses and allied health professionals working in Africa and trains them to become pediatric diabetes educators. ADECA is a hybrid course which includes a combination of E-learning and in person (face-to-face) modules.
## **FID-ISPAD Grant**
This grant is for ISPAD members, preferably below the age of 40. The scope of the research grant is related to the identification of a cure for type 1 diabetes, meaning a procedure or therapy that can ensure the normalization and maintenance over time of a normal glucose balance in the absence of external insulin administration. This category includes projects on pathogenesis, prediction, prevention, beta-cell replacement, organ and cell transplantation, tissue regeneration and stem cells, gene therapy.
Explicitly excluded from funding is research on insulin, drugs, glucose sensor technologies, or insulin infusers, which pertain to pharmaceutical and biotechnology companies. Also excluded is research related to complications of diabetes and research related to type 2 diabetes or forms of diabetes other than type 1 diabetes.
The FID-ISPAD Research Grant program is only open to applicants from non-profit institutions or groups of such institutions. One recipient per year is selected, and receives a funding amount of EUR 25,000 for their research.
Page 31
**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **Changing Diabetes in Children**
Changing Diabetes in Children partnered with ISPAD in 2019-2022 with developing training material and workshops in Cambodia to raise awareness about T1D. The funding came from ISPAD and the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ). This fund/activity has therefore been renamed to ISPAD-CDiC- T1D Training (Cambodia).
**Changing Diabetes in Children (CDIC)** – there is a very recent agreement (2023) with CDIC, which will be relevant for the year end 2023 accounts. Changing Diabetes® in Children is a public-private partnership established in 2009. The partnership provides comprehensive care for children and young people living with type 1 diabetes in low- and middle-income countries. This includes free life-saving medicine and supplies for persons up to 25 years of age.
## **Transfers**
During the year ended 31st December 2022 transfers were made as follows:
Transfers totalling £33,780 to the Allan Drash Fellowship, ISPAD Guidelines and ADECA funds as these were only part funded by restricted funds.
## **14. Analysis of net assets between funds**
## **Analysis of net assets between funds - current year**
|**Unrestricted**
**funds**
**2022**
**£**
Current assets
1,722,251
Creditors due within one year
(543,825)
Creditors due in more than one year
(43,247)
**Total**
1,135,179|**Restricted**
**funds**
**2022**
**£**
135,864
-
-
135,864|**Total**
**funds**
**2022**
**£**
**1,858,115**
**(543,825)**
**(43,247)**
**1,271,043**|
|---|---|---|
## **Analysis of net assets between funds - prior year**
|Current assets
Creditors due within one year
Creditors due in more than one year
**Total**|_Unrestricted_
_funds_
_2021_
_£_
_1,534,577_
_(456,448)_
_(10,268)_
_1,067,861_|_Restricted_
_funds_
_2021_
_£_
_85,008_
_-_
_-_
_85,008_|_Total_
_funds_
_2021_
_£_
_1,619,585_
_(456,448)_
_(10,268)_
_1,152,869_|
|---|---|---|---|
Page 32
**THE INTERNATIONAL SOCIETY FOR PEDIATRIC AND ADOLESCENT DIABETES (A Company Limited by Guarantee)**
## **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022**
## **15. Reconciliation of net movement in funds to net cash flow from operating activities**
|Net income for the year (as per Statement of Financial Activities)
**Adjustments for:**
(Increase)/ decrease in debtors
Increase in creditors
**Net cash provided by operating activities**|**2022**
**£**
**118,174**
**(82,660)**
**120,356**
**155,870**|_2021_
_£_
_266,958_|
|---|---|---|
|||_(145,850)_
_112,922_|
||||
|||_234,030_|
## **16. Analysis of cash and cash equivalents**
|Cash in hand
**Total cash and cash equivalents**|**2022**
**£**
**1,572,277**
**1,572,277**|_2021_
_£_
_1,416,407_|
|---|---|---|
||||
|||_1,416,407_|
## **17. Analysis of changes in net debt**
|Cash at bank and in hand|**At 1 July**
**2020**
**£**
**1,416,407**
**1,416,407**|**Cash flows**
**£**
**155,870**
**155,870**|**At 31**
**December**
**2021**
**£**
**1,572,277**|
|---|---|---|---|
||||**1,572,277**|
## **18. Related party transactions**
The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 December 2022.
Page 33